The renin-angiotensin system (RAS) adversely affects stroke and cardiovascular disease; polymorphisms in genes involved in this system are associated with cardiovascular disease. The aim of the present study was to confirm the genetic risk of these polymorphisms for stroke and cardiovascular events in a cohort study of 515 hypertensive patients in Japan (follow-up period 90.6±30.2 months). The insertion/deletion (I/D) polymorphism of the gene encoding angiotensin-converting enzyme (ACE), the M235T amino acid change in angiotensinogen, and the A1166C polymorphism in angiotensin II type 1 receptor were determined by TaqMan PCR. In Kaplan-Meier analyses, the ACE I/D polymorphism was a risk factor for cerebro-cardiovascular events, especially cardiovascular events (Po0.0001), and the M235T mutation was a risk factor for cardiovascular events (Po0.0105). The cumulative rates of cerebro-cardiovascular end points for the ACE polymorphism were 10.6, 16.4 and 42.2% for the II (n¼207), ID (n¼244) and DD (n¼64) genotype carriers, respectively (Po0.0001). Cox's proportional hazard models revealed that the ACE DD genotype was a risk factor for cerebro-cardiovascular and cardiovascular events (after adjusting for common risk factors), anti-hypertensive treatment and RAS inhibition (Po0.0001). Moreover, after adjustment for the common risk factors left ventricular hypertrophy and previous myocardial infarction/stroke, these phenomena were preserved. Thus, the DD genotype of ACE may be a genetic risk factor for cerebro-cardiovascular disease, especially cardiovascular events, in hypertensive patients in Japan.
INTRODUCTION
Hypertension is a common disorder associated with increased cerebro-cardiovascular disease (CVD) and a leading cause of morbidity and mortality worldwide. 1 A complex interaction of genetic and environmental factors influences CVD. 2 Many reports suggest that the renin-angiotensin system (RAS) has an important role in the development of CVD, including contributions from the vasoactive peptide angiotensin II-produced from angiotensinogen (AGT) by renin and angiotensin-converting enzyme (ACE)-and its receptor, angiotensin II type 1 receptor (AT1R). [3] [4] [5] RAS-component gene polymorphisms such as the M235T single nucleotide polymorphism (SNP) in AGT, the insertion (I)/deletion (D) polymorphisms in ACE, and the A1166C SNP in AT1R have been reported from various laboratories, including our group. Subjects with the TT AGT genotype have 10-20% higher plasma AGT concentrations, 6 and subjects with the ACE D allele exhibit higher levels of serum and tissue ACE. 7, 8 In 1992, the Etude Cas-Temoin de l'Infarctus du Myocarde study demonstrated that subjects with the DD genotype carry a significantly increased risk of myocardial infarction (MI). 9 We reported that subjects with the DD genotype have a higher risk of restenosis after emergency percutaneous coronary transluminal angioplasity, 10 hypertension in males 11 and stroke. 12 We also reported that subjects with the AGT TT genotype are at higher risk for lacunar infarction 13 and history of hypertension, 14 but not stroke. 12 Indeed, the literature contains many reports from other laboratories about these genotypes and cardiovascular disease, but many of these results remain controversial.
A cohort investigation with hypertensive patients could help clarify the genetic risk of RAS polymorphisms for CVD. The GenHAT study, a sub-analysis of the ALLHAT study, reported that the ACE I/D polymorphism conferred no genetic risk for cardiovascular diseases; 15 however, the genetic frequencies of the ACE I/D polymorphism are quite different, and a cohort study of hypertensive patients in Japan was not reported. Here, we investigate whether three RAS genotypes interact with the risk of CVD in hypertensive patients in Japan.
METHODS

Study design and population
This cohort study was designed as a part of the NOn-invasive Atherosclerotic evaluation in Hypertension study. 16 At Osaka University Hospital, a total of 705 serial outpatients who had been diagnosed with essential hypertension were recruited between January 1998 and June 2004. A total of 548 subjects were genotyped for the three polymorphisms (II, ID, DD). A clinical survey of each patient was conducted, but we were unable to obtain sufficient information regarding cardiovascular events and/or mortality from 33 patients, leaving 515 hypertensive patients available for analysis. Hypertension was defined as systolic blood pressure X140 mm Hg, diastolic blood pressure X90 mm Hg, and/or the use of antihypertensive medication. The study protocol was approved by the hospital ethics committee and written informed consent was obtained from all participants. At entry, a total of 276 patients were not receiving treatment with any antihypertensive drug, and 239 patients were treated with one or more antihypertensive drugs as follows: 167 patients with a calcium antagonist, 145 patients with an angiotensin receptor blocker (ARB) and/or with an ACE inhibitor (ACE-I), 50 patients with a b-blocker, 31 patients with a diuretic and 12 patients with an a-blocker.
Follow-up evaluation
Clinical follow-up was conducted by clinical visits, mailed questionnaires and telephone contact every year. The questionnaire included the events of hypertensive complications described below or cause of death; we confirmed the responses in detail by comparing them against patient medical sheets. The primary endpoint of this study was a new onset of CVD, such as stroke, angina pectoris, MI, or heart failure. Specialists diagnosed stroke as a neurological disturbance for at least 24 h and evidence of infarction or bleeding using computed tomography or magnetic resonance imaging. Angina was diagnosed as typical chest pain without elevated levels of creatinine kinase and positive ST change on a stress ECG, and MI as typical chest pain with a more than twofold above normal level of creatinine kinase release and positive ST change on an ECG. Heart failure was diagnosed using American Heart Association criteria. 16 The follow-up duration encompassed the interval from the initial evaluation to the time of event onset or the end of 2009. The average follow-up period ± s.d. was 90.6 ± 30.2 months.
Genotyping
Peripheral venous blood was drawn into pyrogen-free tubes with ethylenediaminetetraacetic acid, then placed on melting ice and centrifuged for 15 min at 1500Âg for 10 min at 4 1C. Plasma was stored at À80 1C, and samples were thawed only once. The conventional genotyping method for screening ACE I/D polymorphisms consists of two steps: a TaqMan PCR and agarose gel electrophoresis. In the present study, we prepared a C allele-specific probe, 5¢-Fam-TGACCTCGTGATCCG-3¢, and a T allele-specific probe, 5¢-Vic-CAGGTCTAG AGAAATG-3¢. We prepared three primers with the ACE sequences: forward, 5¢-CAGTAAGCCACTGCTGGAGACC-3¢ and 5¢-TTAGCCGGGATGGTCTCGAT-3¢; and reverse, 5¢-GGCGAAACCACATAAAAGTGACTG-3¢. Cycling conditions were an initial denaturation at 95 1C for 10 min followed by 45 cycles of 30 s at 95 1C, 60 s at 59 1C and 60 s at 72 1C. The resulting PCR products were separated on 1.5% agarose gels, stained with ethidium bromide and visualized under ultraviolet light. AGT polymorphisms encoding the M235T amino acid substitution, as well as the AT1R polymorphism1166A/C, were determined by amplification with biotinylated primers and hybridization to immobilized sequence-specific oligonucleotides as previously described. 17 
Confounding factors
To clarify the influence of other risk factors on event-free survival for CVD and cardiovascular disease, we estimated four Cox proportional hazard models ( Table 3) . As arterial stiffness measured by pulse wave velocity was an independent risk factor for the occurrence of CVD 16 in the NOn-invasive Atherosclerotic evaluation in Hypertension study, we included pulse wave velocity as a confounding CVD risk factor in addition to age, gender, smoking status, systolic blood pressure, diastolic blood pressure, diabetes mellitus and dyslipidemia in Model 2. To exclude the influences of antihypertensive drugs, we adjusted for CVD risk factors and administration of antihypertensive drugs in Model 3. Our assumption that ACE-Is and/or ARBs impacted the influence of these SNPs has been demonstrated previously; 18 therefore, we also adjusted for CVD risk factors, ACE-I administration, and/or ARB administration in Model 4. To evaluate the influence of high-risk patients included in GenHAT, 15 we selected advanced CVD risk factors such as left ventricular hypertrophy shown on ECG or echocardiography, and previous MI and stroke (Table 3b) .
Statistical analysis
Statistical analysis was performed with analysis of variance and Student's t-test. An event-free curve was estimated using the Kaplan-Meier method. We used a log-rank test and non-adjusted Cox proportional hazard models to evaluate the relative risk and 95% confidence intervals. Baseline clinical variables for these patients were analyzed with the Cox proportional hazard model after adjusting for confounding factors, and the hazard ratio with 95% confidence intervals was given for each factor. Analyses were performed with commercially available software (JMP ver. 8; SAS Inc., Cary, NC, USA). A value of Po0.05 was considered statistically significant.
RESULTS
Kaplan-Meier survival curves according to AGT, ACE I/D and AT1R polymorphisms
The observed frequencies of the RAS polymorphisms were in HardyWeinberg equilibrium (Table 1) . Kaplan-Meier analysis indicated a significant difference in the incidence of CVD according to the ACE I/D polymorphism (Po0.0001), but not according to the AGT or AT1R polymorphisms (Figure 1 ). The AGT polymorphism exhibited a statistically significant difference in cardiovascular events in the Kaplan-Meier survival analysis (P¼0.0105; data not shown). When we performed a Kaplan-Meier analysis classified into a dominant or recessive model group, the TT genotype of AGT showed a significantly higher incidence of cardiovascular diseases (P¼0.0026) and a trend towards a higher incidence of CVD (P¼0.0808) than the MM+MT genotype determined from the AGT and AT1R genotypes.
Baseline characteristics
Our study focused on the ACE I/D polymorphism, and we detected significant differences in diastolic blood pressure and incidence of diabetes among the three genotypes (Table 2a) . To clarify the influence of genetic background on the risk of CVD events, we also analyzed the relationship between CVD events and ACE genotype in patients aged o65 years (n¼298 ; Table 2b ); no significant difference in baseline clinical variables was uncovered in this sub-group.
Clinical outcomes
The cumulative rates of CVD end points were 10.6% (n¼22), 16 .4% (n¼40) and 42.2% (n¼27) in subjects with the II (n¼207), ID (n¼244) and DD genotypes (n¼64), respectively (Po0.0001). There was a significant difference in CVD incidence in subjects with ACE polymorphisms (DD vs. ID and II; Po0.0001; Figure 2 ), especially for cardiovascular disease, in the Kaplan-Meier survival curves. The Cox proportional hazard model indicated that the DD genotype was an independent risk factor for CVD and cardiovascular Prognostic impact of ACE polymorphisms N Kato et al diseases, both without adjustment and after adjustment (Table 3a) for CVD risk factors (Po0.0001). The analysis adjusted for advanced CVD risk factors is shown in Table 3b . In this model, we found that the DD genotype was an independent risk factor for CVD and cardiovascular diseases, both without adjustment and with adjustment for advanced CVD risk factors. Moreover, we also found that the DD genotype was an independent low-risk factor for stroke after adjustment for advanced CVD risk factors (P¼0.0476).
Clinical outcomes and antihypertensive treatment
Realizing that CVD events are reduced by anti-hypertensive treatment, we evaluated the Cox proportional hazard model after adjustment for CVD risk factors and antihypertensive treatment in Model 3 (Tables  3a and 3b ). The DD genotype was an independent risk factor for CVD and cardiovascular diseases after adjustment for anti-hypertensive treatment and CVD risk factors (Table 3a ; Po0.0001) or advanced CVD risk factors (Table 3b ; Po0.0001). The DD genotype trended toward being an independent risk factor for stroke, but was not statistically significant after adjusting for advanced CVD risk factors and anti-hypertensive treatment (Table 3b ; P¼0.0537). In Model 4, we excluded the influence of RAS inhibition by adjusting for CVD risk factors and treatment with ACE-Is and/or ARBs (Table 3a) , and advanced CVD risk factors and treatment with ACE-Is and/or ARBs (Table 3b ). The DD genotype was an independent risk factor for CVD and cardiovascular diseases after adjusting for ACE-I and/or ARB treatment (Tables 3a and 3b ; Po0.0001). The DD genotype trended towards being an independent low-risk factor for stroke in Model 4, but was not statistically significant after adjusting for advanced CVD risk factors and treatment with ACE-Is and/or ARB (Table 3b ; P¼0.0552).
Clinical outcomes in patients under 65 years of age To emphasize the genetic influences of ACE polymorphisms on the occurrence of CVD, we performed a sub-analysis in patients under 65 years of age (Tables 3c and 3d ). The DD genotype was an independent risk factor for CVD and cardiovascular diseases after adjustment for anti-hypertensive treatment and CVD risk factors (Table 3c ; Po0.0001) or advanced CVD risk factors (Table 3b ; Po0.005) in these patients.
DISCUSSION
Although several previous studies have investigated the associations among polymorphisms in the RAS genes and CVD, to our knowledge this is the first study to investigate the associations among the RAS polymorphisms and CVD using a hospital-based cohort study of hypertensive patients in Japan. In this prospective cohort of 515 hypertensive patients, we demonstrated the deleterious effects of the D allele of the ACE I/D polymorphism on CVD, especially regarding cardiovascular disease. Moreover, we detected no association between the AT1R polymorphism and CVD events; however, the AGT polymorphism appeared to have an influence on the incidence of cardiovascular diseases in a Kaplan-Meier analysis. In cross-sectional studies, the ACE DD genotype has functioned as a risk factor for CVD in Japan; 10, [19] [20] [21] [22] 23 we confirmed this risk in our cohort. Subjects with the DD genotype exhibited higher tissue ACE activity and increased ACE expression in the plaque of acute coronary syndrome, observations that may explain why hypertensive patients with the DD genotype have a higher incidence of cardiovascular disease. In contrast, in the GenHAT study, 15 the ACE I/D genotype was not a predictor of CVD, nor did it modify the response to antihypertensive treatment. A major difference between the present cohort study and the GenHAT study is the race of the participants. It is well known that the genetic frequency of the ACE I/D polymorphism differs greatly between Caucasians and Asians, including Japanese. In the present study, the frequencies of the II/ID/DD polymorphisms were 40.2/47.4/12.4%, respectively, and the allele frequencies of I/D were 63.9/36.1%, respectively. In the GenHAT study, the frequencies of the II/ID/DD polymorphisms were 19.7/50.0/30.3%, respectively, and the allele frequencies of I/D were 44.7/55.3%, respectively. The inclusion criteria for these two cohort studies were also different; the GenHAT study recruited high-risk hypertensive patients with left ventricular hypertrophy and previous MI and stroke, whereas our study included both low-and high-risk hypertensive patients. To avoid heterogeneity in our study, we adjusted for coronary risk factors included in the GenHAT study, but the relationship between ACE polymorphisms and cardiovascular events did not change. Another difference was that our study population was younger than that in the GenHAT study. We found that the DD genotype was associated with the occurrence of CVD in patients aged o65 years; as shown in a previous report, the effect of this polymorphism decreased with age. 24 As we previously reported, the association between RAS inhibition and ACE I/D polymorphism is very important. 18 Although some studies have reported that administration of ACE-Is and/or ARBs vary the effect of the ACE I/D genotype on cardiovascular events, 25 others have not. 15 Although we only have baseline information about antihypertensive treatments, the ACE DD genotype was an independent risk factor for CVD after adjusting for ACE-I/ARB drugs and antihypertensive drugs. A previous report 26 revealed an association between aldosterone escape and the DD genotype, suggesting an influence by aldosterone escape. Moreover, the DD genotype was an independent risk factor for CVD after adjusting for not only all, but also each antihypertensive drug or statins treatment (data not shown). In the present study, the ACE polymorphism exerted a significant effect on stroke. It is thought that stroke is a blood pressure-dependent event, but in this study patient blood pressure was well controlled, with patients receiving medication that affects stroke occurrence. Although the ACE DD genotype was associated with a higher incidence of CVD, the M235T SNP of AGT and the A1166C SNP of AT1R also exhibited small associations. In the present study, only the TT genotype of the M235T AGT SNP was associated with a lower event survival ratio compared with the MT+MM genotype. As the frequencies of the TT genotype in AGT and the CC genotype in AT1R are low in the general population, a larger cohort study would be required to confirm this association. However, this is the first report to demonstrate the possibility of a genetic risk of the M235T AGT SNP for CVD in hypertensive patients. Although this evidence is not directly reflective of common clinical practice, we propose to tailor treatment to the patient by genotyping patients with hypertension.
Study limitations
The present study had several limitations. First, this cohort study was a hospital-based single-center study rather than a multi-center study.
To avoid study bias and confirm the present observations, a larger cohort and multi-center trials are needed. Second, patients who enrolled in this study received many types of antihypertensive treatment, and some patients received agents that affected CVD. Recent reports indicate that treatment with ACE-Is, ARBs, or statins improves arterial stiffness, suggesting that treatment with these medications may contribute to better survival outcomes.
